Crocs Inc. diskutieren
Crocs Inc.
WKN: A0HM52 / Symbol: CROX / Name: Crocs / Aktie / Textilien & Bekleidung / Small Cap /
76,09 €
2,12 %
Crocs, Inc. (NASDAQ: CROX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $167.00 price target on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) was upgraded by analysts at OTR Global from a "mixed" rating to a "positive" rating.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $154.00 price target on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at Monness Crespi & Hardt from $140.00 to $170.00. They now have a "buy" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at Stifel Nicolaus from $140.00 to $158.00. They now have a "buy" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at Barclays PLC from $167.00 to $169.00. They now have an "overweight" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at Wedbush from $156.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at Bank of America Co. from $160.00 to $187.00. They now have a "buy" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $170.00 price target on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target lowered by analysts at Barclays PLC from $169.00 to $164.00. They now have an "overweight" rating on the stock.
Ratings data for CROX provided by MarketBeat
Hey there! I've been keeping an eye on Crocs, and I've got to say, I'm feeling pretty bullish about this funky footwear giant. Their recent performance has been nothing short of impressive, with record-breaking sales and expanding profit margins. It's like they've found the perfect recipe for success in the shoe game!
What really catches my eye is their ability to generate consistent profits and grow earnings per share. It's not just a flash in the pan – we're talking steady, sustainable growth here. And let's not forget about the insiders who have a significant stake in the company. When the bigwigs are invested, you know they're committed to making this ship sail smoothly.
Sure, there's been some recent insider selling, but that's not uncommon and doesn't necessarily spell doom. The stock's current valuation looks pretty reasonable too, trading at a P/E ratio lower than both the industry average and its own historical median. It's like finding a pair of Crocs on sale – you know they're comfy, but now they're a bargain too!
The company's strong free cash flow is another feather in their foam resin cap. They're using it wisely, paying down debt and buying back shares. It's like they're tidying up their financial house, making it even more attractive to potential investors.
Of course, there's always risk in the stock market – it's as unpredictable as fashion trends! But with Crocs' solid fundamentals, innovative product line, and smart financial management, I think they're well-positioned to weather any storms and potentially deliver some sweet returns. So, while I can't tell you what to do with your money, I'm personally feeling pretty optimistic about Crocs' future. It might just be time to slip into this stock!
Crocs, Inc. (NASDAQ: CROX) was upgraded by analysts at Williams Trading from a "hold" rating to a "buy" rating. They now have a $163.00 price target on the stock, up previously from $135.00.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $170.00 price target on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target raised by analysts at KeyCorp from $149.00 to $155.00. They now have an "overweight" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $182.00 price target on the stock.
Ratings data for CROX provided by MarketBeat
Crocs looks like a solid buy right now. Their Q3 earnings are coming up, and analysts are optimistic. The North American market seems stable, and their international expansion is going well, especially in China and Australia. Their collaborations with popular brands are driving engagement, and they're branching out into new product lines like sneakers. The financials look good too - their profit margins are strong at over 20%, and they've been growing net income at nearly 30% annually over the past 5 years. The stock's trading at a pretty reasonable P/E of around 13, which seems cheap for a company with this kind of growth. There are some headwinds like slowing consumer demand, but overall Crocs seems well-positioned to keep performing. I'd say it's worth taking a bite out of this comfy stock.
Crocs, Inc. (NASDAQ: CROX) had its price target lowered by analysts at Barclays PLC from $164.00 to $125.00. They now have an "overweight" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target lowered by analysts at Robert W. Baird from $190.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for CROX provided by MarketBeat
Crocs, Inc. (NASDAQ: CROX) had its price target lowered by analysts at Monness Crespi & Hardt from $170.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for CROX provided by MarketBeat


.png?locale=de)

Neueste Beiträge
Cowen_Inc in Rhythm Pharmaceuticals diskutieren